

Impact of mānuka honey on symptoms and quality of life in individuals with functional dyspepsia: a feasibility study protocol.

Laura Ombasa, Jody Miller, Lara Ware, Holly Abbotts-Holmes, Jeffrey Tang, Oliver Gasser, Karl Fraser, Simone Bayer, Roslyn Kemp, Rory Costello, Andrew Highton, Jackie Evans, Troy Merry, Michael Schultz, Chris Frampton, Richard Gearry, Warren McNabb, Nicole Roy

Submitted to: JMIR Research Protocols
on: September 14, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 37

 Figures 38

 Figure 1..... 39

CONSORT (or other) checklists..... 40

 CONSORT (or other) checklist 0..... 41

 CONSORT (or other) checklist 0..... 41

Impact of m?nuka honey on symptoms and quality of life in individuals with functional dyspepsia: a feasibility study protocol.

Laura Ombasa^{1, 2, 3}; Jody Miller^{1, 3}; Lara Ware^{1, 3}; Holly Abbotts-Holmes^{1, 3}; Jeffrey Tang^{3, 4}; Oliver Gasser^{3, 4}; Karl Fraser⁵; Simone Bayer^{3, 6}; Roslyn Kemp⁷; Rory Costello⁷; Andrew Highton⁷; Jackie Evans⁸; Troy Merry⁸; Michael Schultz⁹; Chris Frampton¹⁰; Richard Gearry^{3, 6}; Warren McNabb^{2, 3}; Nicole Roy^{1, 2, 3}

¹ Department of Human Nutrition University of Otago Dunedin NZ

² Riddet Institute Massey University Palmerston North NZ

³ High-Value Nutrition National Science Challenge Auckland NZ

⁴ Malaghan Institute of Medical Research Wellington NZ

⁵ AgResearch Palmerston North NZ

⁶ Department of Medicine, University of Otago Christchurch NZ

⁷ Department of Microbiology and Immunology, University of Otago Dunedin NZ

⁸ Comvita NZ Limited Paengaroa NZ

⁹ Department of Medicine University of Otago Dunedin NZ

¹⁰ Statistecol Christchurch NZ

Corresponding Author:

Jody Miller

Department of Human Nutrition
University of Otago
Dunedin
NZ

Abstract

Background: Functional dyspepsia is a common gastrointestinal condition characterised by symptoms such as epigastric pain or burning, early satiety, or postprandial fullness, that negatively impacts quality of life, work productivity and healthcare costs. A lack of well-defined causes for the condition limits effective treatment options. Consumers around the world report using m?nuka honey as a treatment for gastrointestinal symptoms, including dyspepsia, although clinical evidence supporting such use is limited. Pre-clinical studies indicate that unique compounds in m?nuka honey may have bioactive properties that could prevent gastrointestinal inflammation. Recently, a 3,6,7 trimethylxanthine (Lepterdine™), a natural pteridine compound in m?nuka honey, was shown to inhibit enzymes involved in gastrointestinal inflammation in in vitro studies. Therefore, Lepterdine™ standardised m?nuka honey may deliver digestive health benefits.

Objective: The aim of this feasibility study is to gather data required to estimate sample size and support study logistics to design future trials. The primary objective will be preliminary assessments of the impact of Lepterdine™ standardised m?nuka honey on digestive symptom severity and quality of life in subjects with mild to moderate functional dyspepsia. Other feasibility objectives include assessing the biological responses to m?nuka honey standardised to medium and high levels of Lepterdine™, and concentrations of m?nuka honey-derived metabolites in blood and urine following consumption.

Methods: This is a three-arm, parallel, controlled, double-blind, randomised feasibility study. Seventy-five healthy adults with symptoms of functional dyspepsia (Rome IV Criteria) and mild-to-moderate severity of dyspepsia (Short Form Leeds Dyspepsia Questionnaire) were recruited between October 2022 and September 2023. Participants were randomised into one of three groups: 1) m?nuka honey standardised to contain 10 mg/kg Lepterdine™; 2) m?nuka honey standardised to contain 40 mg/kg Lepterdine™; or 3) honey maple flavoured syrup control. After a two-week lead-in period, participants consumed 10 g of their respective intervention twice daily for six weeks. Throughout the study, participants completed daily bowel movement diaries and validated weekly questionnaires about their gastrointestinal symptoms and quality of life. Three-day diet records and stool samples were collected at baseline and end of the intervention. Blood samples were collected at baseline, weeks two and four, and at the end of the intervention. In addition, six healthy participants without symptoms of functional dyspepsia were recruited to undergo an acute five-hour assessment for the appearance of Lepterdine™ and related metabolites in plasma and urine following consumption of Lepterdine™ standardised m?nuka honey. The study was approved by the Northern B Health and

Disability Ethics Committee.

Results: At the time of writing, laboratory and data analyses are being undertaken. The results of the primary and secondary outcomes will be published in peer-reviewed journals.

Conclusions: This study will provide essential information on the potential efficacy and suitability of Leptiridine™ standardised m?nuka honey to design future clinical trials investigating the effect of Leptiridine™ standardised m?nuka honey for the treatment of symptoms of functional dyspepsia. Clinical Trial: Australian New Zealand Clinical Trials Registry, Trial Number ACTRN12622001140741p

(JMIR Preprints 14/09/2024:66417)

DOI: <https://doi.org/10.2196/preprints.66417>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in a JMIR journal, my full manuscript will be made available to all users.

No. Please do not make my accepted manuscript PDF available to anyone.

Original Manuscript

Impact of mānuka honey on symptoms and quality of life in individuals with functional dyspepsia: a feasibility study protocol.

Ombasa, L.G.^{1,2,3}, Miller, J.C.^{1,3}, Ware, L.^{1,3}, Abbotts-Holmes, H.^{1,3}, Tang, J.^{3,4}, Gasser, O.^{3,4}, Fraser, K.^{3,5}, Bayer, S.B.^{3,6}, Kemp, R.A.⁷, Highton, A.J.⁷, Costello, R.M.⁷, Evans, J.C.⁸, Merry, T.L.⁸, Schultz, M.^{2,9}, Frampton, C.M.A.^{6,10}, Gearry, R.B.^{3,6}, McNabb, W.C.^{2,3}, Roy, N.C.^{1,2,3}

¹Department of Human Nutrition, University of Otago, Dunedin, New Zealand

²Riddet Institute, Massey University, Palmerston North, New Zealand

³High-Value Nutrition National Science Challenge, Auckland, New Zealand

⁴Malaghan Institute of Medical Research, Wellington, New Zealand

⁵AgResearch, Palmerston North, New Zealand

⁶Department of Medicine, University of Otago, Christchurch, New Zealand

⁷Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

⁸Comvita NZ Limited, New Zealand

⁹Department of Medicine, University of Otago, Dunedin, New Zealand

¹⁰Statistecol, Christchurch, New Zealand

Correspondence:

Nicole Roy nicole.roy@otago.ac.nz and Jody Miller jody.miller@otago.ac.nz

Abstract

Background

Functional dyspepsia is a common gastrointestinal condition that negatively impacts quality of life, and increases healthcare costs. A lack of well-defined causes for the condition limits effective treatment options. Consumers around the world report using mānuka honey to treat gastrointestinal symptoms, including dyspepsia, although clinical evidence supporting such use is limited. Pre-clinical studies indicate that mānuka honey has unique bioactive compounds that could prevent

gastrointestinal inflammation. Recently, a 3,6,7 trimethylmazine (Lepteridine™), a natural pteridine compound in mānuka honey, was shown to inhibit enzymes involved in gastrointestinal inflammation in *in vitro* studies. Therefore, Lepteridine™ standardised mānuka honey may deliver digestive health benefits.

Objectives

The aim of this feasibility study is to gather data required to estimate sample size and support study logistics to design future trials. The primary objective will be preliminary assessments of the impact of Lepteridine™ standardised mānuka honey on digestive symptom severity and quality of life in subjects with mild to moderate functional dyspepsia. Other feasibility objectives include assessing the biological responses to mānuka honey standardised to medium and high levels of Lepteridine™, and concentrations of mānuka honey-derived metabolites in blood and urine following consumption.

Methods

This is a three-arm, parallel, controlled, double-blind, randomised feasibility study. Seventy-five healthy adults with symptoms of functional dyspepsia (Rome IV Criteria) and mild-to-moderate dyspepsia severity (Short Form Leeds Dyspepsia Questionnaire) were recruited between October 2022 and September 2023. Participants were randomised into one of three groups: 1) mānuka honey standardised to contain 10 mg/kg Lepteridine™; 2) mānuka honey standardised to contain 40 mg/kg Lepteridine™; or 3) honey maple flavoured syrup control. After a two-week lead-in period, participants consumed 10 g of allocated intervention twice daily for six weeks. Throughout the study, participants completed daily bowel movement diaries and validated weekly questionnaires about their gastrointestinal symptoms and quality of life. Three-day diet records and stool samples were collected at baseline and end of the intervention. Blood samples were collected at baseline, weeks two and four, and at the end of the intervention. In addition, six healthy participants without

symptoms of functional dyspepsia were recruited to undergo an acute five-hour assessment for the appearance of Lepteridine™ and related metabolites in plasma and urine following consumption of Lepteridine™ standardised mānuka honey. The study was approved by the Northern B Health and Disability Ethics Committee.

Results

Initial analysis includes 68 participants, with laboratory and data analyses being undertaken as of March 2024. The results of the primary and secondary outcomes will be published in peer-reviewed journals.

Conclusion

This study will provide essential information on the potential efficacy and suitability of Lepteridine™ standardised mānuka honey for designing future clinical trials investigating its effect in treating symptoms of functional dyspepsia.

Clinical Trial Registration

Australian New Zealand Clinical Trials Registry; Trial Number [ACTRN12622001140741p](https://www.anzctr.org.au/Trial/Registration/Trial.jsp?ACTRN12622001140741p)

Keywords: functional dyspepsia, quality of life, mānuka honey, Lepteridine, randomised controlled trial, feasibility protocol

Introduction

Functional dyspepsia (FD) is a common gastrointestinal disorder characterised by epigastric pain, early satiety, postprandial fullness and epigastric burning sensations that occur without explanation of the symptoms at upper gastrointestinal endoscopy [1]. The prevalence of FD ranges from 10 to

40% and varies depending on the country or criteria used to define its presence [2]. FD is more common in women than in men, which could be attributed to sex-specific differences in gastrointestinal motility caused by sex hormones, responses to pain signalling or health-seeking behaviour [3]. Currently, the pathophysiology of FD is only partially elucidated, with growing evidence implicating multifactorial causes [4]. Several pathophysiologic mechanisms have been proposed to cause FD [1, 4] which include altered gastric motility [5, 6], visceral hypersensitivity [7, 8], altered gut microbiota composition [9-11], and gastroduodenal inflammation characterised by lymphocyte infiltration and increased eosinophils [12-14]. Psychological factors also play a crucial role in FD, as the gut and brain communicate through the enteric nervous system and hypothalamic pituitary adrenal axis [15].

Functional dyspepsia is not life threatening but can negatively impact health-related quality of life [16], work productivity [17], and increase healthcare expenses [18]. This disorder is complex and challenging to treat, primarily because of its heterogeneous nature and absence of well-defined underlying causes [19, 20]. Current treatment options for FD include the eradication of *Helicobacter pylori* (*H. pylori*), the use of proton pump inhibitors, H₂ receptor antagonists, antidepressants, and/or prokinetic agents [19]. These existing treatments often fail to provide consistent relief, and side effects can limit their use [21]. Individuals often seek alternative therapies because of the severe impact of FD on health-related quality of life and suboptimal treatment options, however, these alternative therapies lack clinical evidence.

Honey has been an essential component of ancient medicine, with uses including preventing and treating digestive diseases [22]. Honey contains many nutrients: sugar, proteins, enzymes, vitamins, amino acids, and many phytochemicals [23]. The composition of honey varies depending on the flora from which nectar is collected, the type of bee that produces it, and environmental conditions. The variation in the composition of honey contributes to its diverse potential health benefits, making it

useful in therapeutic therapies [24]. Studies suggest that honey could have gastroprotective properties due to its anti-inflammatory, antimicrobial and antioxidant properties [25, 26]. In addition, honey could help promote beneficial gut microbiota [27-29]. Few studies have examined the effect of honey on FD. For example, when combined with standard treatment, the adjuvant supplementation of honey-based formulation of *Nigella sativa* significantly improved the symptoms of FD [30]. A clinical trial that examined the effects of honey and diet education on FD reported improvements in symptoms, although honey alone did not have significant gastrointestinal effects [31]. A significant improvement in symptoms was observed when honey was combined with proton pump inhibitors in children with FD[32]. However, these studies use honey as an adjuvant intervention to standard therapy, making it difficult to attribute any observed effects to honey.

Mānuka honey is a mono-floral honey produced from the nectar of the *Leptospermum scoparium* tree. Mānuka honey has unique bioactive compounds, including phenolic acids, flavonoids, 1,2-dicarbonyl compounds, and pteridines [33]. Studies suggest these unique compounds [34] elicit anti-inflammatory, antioxidant, or antibacterial effects [35-37]. *In vivo* studies indicate mānuka honey may have gastroprotective properties by inhibiting gastric lesions and preserving gastric mucosal glycoproteins [35, 36, 38]. Mānuka honey also decreased the production of inflammatory cytokines such as tumour necrosis factor-alpha (TNF- α), interleukin-1 beta and interleukin-6 [35, 37]. These proinflammatory cytokines may play a key role in gastric lesions, as TNF- α is a key modulator in gastric mucosal cell death [39]. Different doses of mānuka honey provided protection against trinitrobenzene sulfonic acid-induced colitis in Wistar rats [36] and acetic acid-induced gastric lesions in Sprague-Dawley rats [35]. Furthermore, four weeks of oral application of mānuka honey led to changes in gut microbiota composition in mice with colorectal cancer [27]. While these studies suggest a plausible link between mānuka honey and digestive health, no clinical trials have investigated its effect in FD.

3,6,7 trimethyl lumazine (Lepteridine™) is a recently discovered pteridine derivative unique to mānuka honey [40]. Pteridines are aromatic compounds that are produced naturally by living organisms. They play essential metabolic roles, including enzymatic co-factors and immune system activation molecules. They may also have activity in the treatment of chronic inflammatory diseases [41], with methotrexate, a pteridine derivative medicine, being used in the treatment of inflammatory bowel disease, rheumatoid arthritis and psoriasis. Recent *in vitro* studies have shown that Lepteridine™ may contribute to the anti-inflammatory properties of mānuka honey by inhibiting the proteolytic activity of matrix-metalloproteinase-9 (MMP-9) [42] which is key in maintaining the integrity of the gastric mucosa and promoting wound healing [43, 44]. Lepteridine™ might work synergistically with other bioactive properties in mānuka honey to amplify its anti-inflammatory properties. However, the natural variation in Lepteridine™ concentration in mānuka honey necessitates the need for standardised formulations to ensure consistent therapeutic efficacy [42]. Currently, no clinical trials have been conducted to evaluate the potential therapeutic effects of mānuka honey standardised to Lepteridine™ concentration in treating FD.

Objectives

The SOOTHE (Study of Mānuka Honey fOr DigesTive HEalth) feasibility study aims to gather information required to design and undertake future clinical trials investigating the effect of Lepteridine™ standardised mānuka honey on FD. The primary objective is to assess the effect of six weeks of consumption of Lepteridine™ standardised mānuka honey on symptom severity and quality of life in functional dyspepsia. This will be measured by changes in global Nepean Dyspepsia Index scores from baseline to end of intervention. Data on recruitment timeframe, strategies to improve recruitment, potential issues with adherence and attrition, and strategies to optimise adherence shall also be collected.

Secondary objectives include examining changes in Patient-Reported Outcome Measurement Information System (PROMIS Gastrointestinal, Anxiety and Depression) scores, immune parameters

and the gut microbiota composition between the Lepteridine™ standardised mānuka honey and control groups. The study will also explore the pharmacokinetic profile of Lepteridine™ and other mānuka honey-derived metabolites in plasma and urine following acute consumption of Lepteridine™ standardised mānuka honey.

Methods

Study design

The protocol was developed in accordance with the Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) guidelines for clinical trial protocols [45]. Appendix 1 provides a complete checklist of SPIRIT Outcomes 2022.

Study overview

This was a three-arm, parallel, controlled, double-blind, randomised feasibility study in participants with functional dyspepsia with mild to moderate symptoms. The study duration was ten weeks, consisting of a two-week lead-in phase, a six-week intervention phase and a final two-week follow-up phase (figure 1). During the intervention phase, participants in two arms consumed 10 g of mānuka honey, standardised to contain either 10 mg or 40 mg/kg of Lepteridine™ twice daily. The third arm received 10 g of honey maple-flavoured syrup twice daily as a placebo control.

Before the study commenced, a mutually agreed schedule was discussed and set with each participant to ensure they understood all expected clinic visits and the study timeline. However, participants' needs were accommodated if they could not come on a scheduled clinic day by allowing them to attend the clinic up to one week later. This approach aimed to reduce the risk of participants running short of the intervention product and dropping out due to scheduling issues.




Figure 1. Study flow chart; BID (bis in die): 10 g of allocated intervention before twice daily, before breakfast and dinner.

Recruitment

Recruitment was conducted between October 2022 and December 2023. Adults from the community who self-identified as having mild-moderate symptoms of FD contacted the study team (via email, phone, or text) in response to study posters, radio, newspaper, or social media (Facebook and Instagram) advertisements, word-of-mouth referrals, or from community outreach activities undertaken by the study team and a specialist clinical trial recruitment company (Trialfacts, Australia). Potential participants were then given a unique identifier link to the online study information sheet and consent form. All eligible respondents were allowed sufficient time to consider participation in the study. Once informed consent was given, they completed a screening questionnaire to ascertain their eligibility for participation in the study. The screening questionnaire included the Rome IV Diagnostic Questionnaire for Functional Gastrointestinal Disorders in Adults (R4DQ) [46], the Short-Form Leeds questionnaires (SF-LDQ) [47] and general health questionnaires. Research staff reviewed the completed questionnaires, and eligible respondents were invited to a screening visit at research clinics in Dunedin or Christchurch, New Zealand.

Eligibility criteria

All interested respondents were assessed for eligibility based on the following inclusion and exclusion criteria.

Inclusion criteria

Participants were eligible if they met the following criteria:

- Aged between 18 to 70 years.
- BMI between 18.5 to 40 kg/m²
- Met the ROME IV criteria for diagnosing FD.
- Had SF-LDQ score < 23 (to exclude people with very severe dyspepsia symptoms).
- Willing to consume 10 g of intervention twice daily, provided during the intervention period.

Exclusion criteria

- Unwilling to give informed consent.
- Taken antibiotics within the month before starting the study.
- Use of certain prescribed medication or recreational drugs: Proton Pump Inhibitors, H2-receptor antagonists, antacids, mucosal protectants, prokinetics, antidepressant drugs if they were prescribed solely for controlling dyspepsia symptoms, anticholinergic agents, cholinergic agents, and over-the-counter herbal remedies used to treat dyspepsia symptoms (participants were asked to stop taking these for two weeks before the start of the study if they were to be eligible for recruitment)
- *H. pylori*-positive (physician-diagnosed or identified during screening) or undertaking treatment for the infection.
- Alarm features associated with significant gastrointestinal or other disorders, such as

abdominal pain that wakes the participant from sleep; frequent vomiting; family history of gastrointestinal malignancies suggestive of a significant hereditary cancer syndrome; lower gastrointestinal bleeding; odynophagia; dysphagia.

- Medical history of upper gastrointestinal surgery or other significant disorders (e.g. inflammatory bowel disease, coeliac disease), significant cardiorespiratory disease, diabetes mellitus, significant bleeding disorders, sleep disorders, and active psychiatric conditions (major depressive disorder, schizophrenia).
- Significant weight loss (> 5% of total body weight) during the six months before starting the study.
- Significant dietary changes within the month before starting the study (i.e., being on a controlled diet or dietary weight loss regimen).
- Intolerance or allergy to honey and bee products.
- Pregnancy or breastfeeding
- Smokers
- Excessive alcohol intake > 20 g of pure alcohol (2 drinks)/day on average (> 21 standard drinks a week)
- Inability or unwillingness to comply with the study procedures.

Screening

During the screening visit, research staff provided further information on the study and collected fasted blood samples for standard blood chemistry analyses (e.g., glycated haemoglobin (HbA1c), liver and kidney function, acute inflammation, complete blood count). Participants also provided stool samples within 24 hours after attending the clinic for an *H. pylori*-antigen test. Basic blood chemistry analyses and *H. pylori* antigen testing were conducted by local health clinics. Participants were excluded if either the HbA1c level was above 40 mmol/mol, basic blood chemistry results were

twice the upper limit, or the haemoglobin level was below 120 g/L. To reduce the risk of a false negative *H. pylori* test result, they were asked to stop taking proton pump inhibitors or bismuth preparations two weeks before the screening visit. Height and weight measurements were also taken to calculate body mass index.

Enrolment

Upon enrolment, participants received unique links to study questionnaires. They were also instructed to download an app to monitor daily bowel movements and compliance. The Measurements and Outcomes section provides more details about this.

Study Intervention

The active intervention for this feasibility study was monofloral mānuka honey standardised to contain either 10 or 40 mg/kg of natural Lepteridine™. The concentration of naturally occurring does not correlate with other known compounds found in mānuka honey, such as methylglyoxal (MGO). Lepteridine™ in mānuka honey is derived from the nectar of the mānuka. Naturally, it varies; therefore, to produce a mānuka honey product with standardised Lepteridine™ concentration, testing for the presence and quantity of Lepteridine™ in raw honey drums was undertaken and the resulting drums blended to achieve the desired concentration of Lepteridine™ in the final mānuka honey product [40]. The composition of the intervention products is shown in Table 1. Participants received the study products in unidentifiable sachets containing 10 g of Lepteridine™ standardised mānuka honey or honey maple flavoured syrup solution. Participants took the assigned intervention before breakfast and dinner for six weeks. They were asked to avoid consuming any other honey during the study.

Table 1. Composition of intervention product.

Nutrient/ Component	Mānuka honey ^a	Honey maple flavoured syrup
	Per 100g	^b Per 100g
Energy	1370 kJ	1290 kJ

Carbohydrate	80 g	76 g
Sugars	78 g	76 g
Protein	<1 g	<1 g
Fat	<1 g	<1 g
Sodium	12 mg	18 mg

Source: ^a Comvita New Zealand Ltd; ^b New Zealand Sugar Company Ltd

Randomisation, blinding and allocation

A week before the baseline visit, participants were randomly assigned to a 1:1:1 allocation using randomised permuted blocks (block size 4) to either the Lepterdine™ mānuka honey or control groups. An independent researcher allocated participants to their intervention group using a computer-generated randomisation list.

Participants and the research team were blinded to the intervention allocation. The manufacturer of the honey was responsible for labelling the intervention products to maintain the blinding of research team members. A specified research team member was responsible for enrolling participants, giving the intervention, and managing the stock. Unblinding will only be permissible once the statistical analyses of the primary outcomes are completed.

Measurements

Timing of measurements

After enrolment, study clinic visits were undertaken at baseline, weeks two, four, and six (end of intervention). Currently, there is no information on the potential time course for which a treatment effect might be observed. Therefore, the multiple assessment time points enabled monitoring of potential symptom trends and identify optimal time points when any treatment effect can be observed. Table 2 shows when the study measurements were done. The information from this feasibility study will be used to determine the appropriate timing and selection of sensitive

measurements for future trials.

Measurement	Lead -in Wee k -2	Lead -in Wee k -1	Baselin e	Wee k 1	Wee k 2	Wee k 3	Wee k 4	Wee k 5	Wee k 6	Wee k 7	Follow -up Week 8
Nepean Dyspepsia Index	X		X		X		X		X		X
Anthropometry ^a			X		X		X		X		
3-Day Diet Record		X							X		
Patient Reported Outcomes Measurement Information System	X	X	X	X	X	X	X	X	X	X	X
Daily Bowel Diary	X	X	X	X	X	X	X	X	X	X	X
Blood samples			X		X		X		X		
Stool samples			X						X		

Table 2. Timing of study measurements.

^a Measured height, weight and waist circumference at baseline and week 6; measured weight only at week 2 and 4

Outcome measurements

Primary feasibility measurement

The primary feasibility outcomes are changes from baseline to week six in FD symptoms and FD health-related quality of life, which were assessed using the Nepean Dyspepsia Index (NDI) questionnaire. This is a validated instrument with a two-week recall that evaluates the severity of symptoms and its impact on quality of life [48].

The symptom instrument of the NDI consists of 15 common dyspeptic symptoms which are rated using a Likert scale that evaluates the frequency, intensity, and bothersomeness of each symptom.

The scores for frequency, intensity, and bothersomeness are summed to give a score for each

symptom with a possible score range of 0 to 13. Higher scores represent greater symptom severity. The total symptom score is calculated as the sum of scores for all 15 individual symptoms and can range from 0 to 195. The total symptom scores are not scaled to 100, and no minimum clinically important difference (MCID) had been established [49].

The quality of life component of the NDI includes 25 questions that are summed to form a global score and scores for four subscales (or domains) measuring the impact of the condition on enjoyment of life and emotional well-being, lack of knowledge and control over the illness, disturbance to eating or drinking, and disturbance to sleep. The scores are scaled to 100 and are sometimes reversed so that high scores indicate better quality of life [50]. The quality of life scales can also be weighted to rank the importance of the domain to the respondent. A minimally clinically important difference (MCID) of 10 points has been established for the NDI-weighted quality of life instrument [48].

In addition to changes in mean scores, responder analyses will be conducted based on the percent of participants who demonstrated improvement in NDI scores from baseline to follow-up of 10%, 20%, 30% and 40% for symptom severity, and 10, 20, and 30 points for quality of life. Furthermore, the percent of participants reporting an improvement equal to or exceeding the MCID for quality of life will be compared between the groups. Effect sizes and standard deviations in symptom changes and quality of life between and within groups will help identify key outcome measures and sample sizes required for future studies.

Additional feasibility information was collected to inform the design of future trials. This information included response and enrolment rates and strategies, data on participant adherence to protocol, perceptions of protocol, and attrition rates. Upon exiting the study, a research team member interviewed the participants on their experiences participating in the study, using open-ended

questions.

Secondary measurements

The Patient-Reported Outcomes Measurement Information System (Gastrointestinal, Anxiety and Depression) was collected weekly. This validated system with multiple domains evaluates patient-reported outcomes that significantly impact quality of life [51]. Measures from the gastrointestinal, anxiety and depression domains were used as gastrointestinal disorders can impair health-related quality of life, leading to physical and mental distress [52]. The measures used evaluate gastrointestinal symptoms (bowel movements, difficulty in swallowing, belly pain, bloating and reflux), anxiety, and depression by severity rating from “not at all” to “very much” and from “never” to “always” [51]. The data collected will provide additional information on possible beneficial or adverse effects of Lepteridine™ mānuka honey or placebo in individuals with FD.

A daily bowel habit diary was collected upon enrolment and throughout the study via a mobile app or paper version. The diary provided a comprehensive record of the participants' bowel habits. It had variables on the frequency of bowel movements, which included questions on spontaneity and completeness of bowel movement, ease of defecation/level of straining, and stool form based on the Bristol Stool Scale [53].

A three-day weighed food record was collected a week before baseline and during week six. Participants were given an electronic dietary scale (Model 1023 WHDR 14, Salter Electronic, Salter House Wares Ltd, Kent, UK) to weigh the food items they consumed. They also received verbal and written instructions on completing the food record, which covered two non-consecutive weekdays and one weekend. The food record included written prompts for detailed information about time, place, type of food or drink, brand details, preparation/cooking methods, quantity, and a section for

details on recipes. Participants were asked to record details that could have affected their usual food intake. Participants completed a paper-based version of the three-day weighed food record during the week before their baseline and week six visits and returned the records during their respective visits. The food records were reviewed by a member of the research team at the time of collection, and queries were clarified with the participant. Data from the food records will be entered into a dietary analysis software, FoodWorks 10 (Version 10.0, Xyris Brisbane, Australia, 2019). The New Zealand Food Composition Database (FOODfiles 2018 (Version 1.0), The New Zealand Institute for Plant and Food Research Limited and the New Zealand Ministry of Health) will be used to estimate energy and nutrient intakes. This data will be used to determine habitual food intake and identify dietary patterns and symptom-triggering foods. The findings will then be linked to symptom severity and gut microbiota.

Biological measurements

Blood samples

A trained phlebotomist collected fasting peripheral blood at each visit (baseline, week two, week four and week six). Blood was collected into 10 ml EDTA tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) for peripheral blood mononuclear cells (PBMC) extraction, two EDTA tubes (4 mL each) to measure insulin, glucose and alpha-1 acid glycoproteins (AGP-1) levels and one serum tube without clot activators (4 mL) to measure cytokine, matrix metalloproteinase-9 (MMP-9), lipid and high sensitive C-reactive proteins (Hs-CRP) concentrations. Blood samples collected in the EDTA tubes were kept in a chill box with ice packs until processing. Blood samples collected in the serum tubes were kept at room temperature for 45 minutes to allow coagulation before processing. Vacutainers (excluding those for PBMC extraction) were centrifuged at 2200 g for 10

minutes at 4°C, and aliquots were stored at -80°C until analysis.

The PBMC were extracted using standard procedures (Appendix 1) at the Department of Microbiology and Immunology, University of Otago, Dunedin and Mātai Hāora - Centre for Redox Biology and Medicine laboratory at the University of Otago, Christchurch. The extracted cells were stored in liquid nitrogen until analyses at the Malaghan Institute of Medical Research (Wellington, New Zealand). Immuno-profiling of the PBMC, including phenotypic and functional markers, will be performed using spectral flow cytometry.

Plasma cytokines including Interleukin (IL) 1 β , IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33, interferon- α 2 (IFN- α 2), interferon- γ (IFN- γ), TNF- α and monocyte chemoattractant protein-1 (MCP-1) will be measured using a cytokine bead assay (MILLIPLEX® MAP Kit Human Cytokine Chemokine Magnetic Bead Panel Immunology Assay, Millipore, MO, USA) as per manufacturer's instructions at the Malaghan Institute of Medical Research (Wellington, New Zealand).

Plasma lipids, Hs-CRP and insulin concentrations will be measured using enzymatic assays (Abbott C series analyser, Abbott Diagnostics), immunoturbidimetric assay (Cobas c311 analyser, Roche Diagnostics) and Cobas e411 analyser Roche Diagnostics respectively at the Canterbury Health Laboratories (Christchurch, New Zealand). The remaining plasma and serum samples will be analysed at the Department of Human Nutrition, University of Otago, Dunedin. For this, serum MMP-9 concentration will be measured using enzyme-linked immunosorbent assay (Human ELISA Kit, Invitrogen, ThermoFisher Scientific, Vienna, Austria), plasma glucose will be measured by enzymatic assays (Abbott C Series analyser, Abbott Diagnostics, Illinois, USA), and AGP will be measured using immunoturbidimetric assay (Cobas c311 analyser, Roche Diagnostics, Germany).

Stool samples

Once enrolled, participants collected a stool sample using the provided OMNIgene®.GUT|OM-200 (DNA Genotek Inc., Ottawa, ON, Canada) stool kit 24 hours before the clinic day at baseline and week 6. The samples were kept at room temperature until processing was done within a week. Two aliquots (2 g each) of stool samples were stored at -80° C until analysis.

DNA was extracted from the stool samples using the Macherey-Nagel™ NucleoSpin™ DNA (Dünen, Germany) stool kit per the manufacturer's instructions. Only data relevant for analysing the gut microbiome composition was extracted. Long-read Oxford Nanopore sequencing will be used for full-length 16S rRNA gene sequencing (~1,500bp) [54] to capture information from all nine hypervariable 16S regions. Nanopore-generated sequence reads, which are re-base-called using "Super high accuracy base-calling" post-run, will be passed through FastQC and then the standard EPI2ME amplicon workflow using the SILVA-138 database for taxonomic assignment.

Leptericidine™ metabolites acute study

As a preliminary investigation into the post-prandial absorption and excretion of selected mānuka honey-derived compounds, a randomised, cross-over, acute study involving six healthy participants without symptoms of FD was conducted. Each participant attended two clinic visits, where they consumed 20 g of either of the Leptericidine™ standardised mānuka honey formulations (containing 10 mg or 40 mg Leptericidine™). After a one-week wash-out, participants consumed the other formulation. The sequence in which they received the honey was randomly selected.

Blood and urine samples were collected before and after participants consumed the assigned honey. To ensure they were hydrated, participants were asked to drink 250 mL of water every hour. Participants could not eat or drink any other food during the clinic except for the allocated study honey and water. Blood and urine samples were collected over five hours. A cannula was fixed by medically trained personnel to allow multiple blood collection at baseline (fasting samples) and 0.5,

1, 2 and 5 hours after consuming the assigned honey. At each time point, 4 mL of blood was collected in a heparin and EDTA vacutainer. The blood was centrifuged at 3000 g for 10 minutes at 4°C, and aliquots were stored at -80°C. All urine voided during the five-hour clinic was collected into sterile containers and stored at -80°C.

The analytical methods for measuring mānuka honey-derived compounds and metabolites will be based on a previous study that investigated the *in vivo* absorption and metabolism of leptosperin over three hours [55] with amendments as required. Briefly, acidified urine will be extracted using solid phase extraction (Strata-C18E cartridge, 3 mL, 500 mg, Phenomenex, Auckland, NZ), which will be pre-conditioned with methanol and 0.1% acetic acid in water. After washing with 2 mL 0.1% acetic acid in water, metabolites will be eluted with 2 mL methanol and then analysed by liquid chromatography with tandem mass spectrometry (LC-MS/MS). For plasma, 20 µL of the sample will be extracted with 300 µL methanol and the extract will be evaporated and reconstituted in 0.05% formic acid for LC-MS/MS. The analyses will be performed on an EXION high-performance liquid chromatography (HPLC) system fitted with a C18 column (Waters 1.7 µm ACQUITY UPLC BEH C18, 100 x 2.1 mm ID) attached to a SCIEX 6500+ Q-TRAP (AB SCIEX, Melbourne, Australia). Urine samples will be analysed in precursor ion mode for m/z 211 (methyl syringate ion) while the plasma will be analysed in multiple reaction monitoring modes (MRM). Biotransformer 3.0 [56] will be used to predict possible metabolites to extend the list of metabolites provided in Ishisaka et al., 2017 [55]. The metabolites will be quantified using commercial standards where available.

Data analysis

Sample size

The determinant of the sample size for this study was to enable the estimation of the standard

deviation and potential effect size for the primary outcome. This estimation is crucial as it allows for sample size calculation in future trials, ensuring the study's findings are robust and applicable. A sample size of seventy-five gives an estimated degree of freedom to calculate standard deviations, allowing reasonable precision.

Data management

The study will generate quantitative and qualitative data, including questionnaires, laboratory data, clinically relevant information regarding symptoms and face-to-face interviews on participants' perceptions of the study protocol. Only data relevant to answering the research question will be collected. There was no anticipated harm during data collection beyond standard care and everyday life risks.

The data collected was in form of electronic files, Word documents, and a small number of paper-based questionnaires. Study data was collected and managed using the Research Electronic Data Capture (REDCap) tool hosted at the University of Otago. REDCap is a secure web, based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources [57, 58]. It was only accessible to the researchers to contact participants for planned data collection. All participants were assigned a unique study identification (ID) number at the point of obtaining consent, which was recorded on REDCap and used instead of personal identifying information in all other data files. A formal Data Monitoring Committee was not required as the intervention and control treatments in the study were considered sufficiently minimal risk. No harm was anticipated beyond the risks of standard care and everyday life. Data monitoring occurred through weekly meetings of the research team.

Data collection and storage

The researchers collecting data were trained in data collection and maintaining security and health-related confidentiality. Most of the data was collected electronically via the REDCap data capture system using unique identification. Participants who preferred paper-based data collection were accommodated. Paper-based and telephone-collected data was entered directly into the REDCap.

The data files were stored in Excel for raw data and as data analysis files in (R, Stata, or SPSS). This data was only identified by the unique identification of the participant. Participants were identified by researchers only by their unique identification.

Raw data collected in hard copy was stored after electronic data entry as part of the case report form (CRF) in a locked filing cabinet in the Principal Investigator's office. Electronic data files generated in the study were stored on a password-secured University of Otago server or Otago OneDrive cloud storage. These files will be accessed as needed on password-protected computers of named investigators.

Statistical analyses

All statistical analyses will be done using either R version 4.3.2, Stata/SE version 18.0 or IBM® SPSS® version 29. The primary outcome analyses will use the intention-to-treat population (ITT) and per-protocol population (PP). Secondary and exploratory analyses will be conducted with the ITT population. The ITT population will include all randomised participants who took at least one dose of the intervention. The PP population will include those in the ITT who had no major protocol violations, had all the study assessments required to analyse any outcome, and consumed at least 80% of their intervention product. Participants with missing data for a relevant outcome assessment will be imputed using the last observation carried forward.

The primary analysis will compare the overall NDI score changes for symptom severity and quality of life from baseline to week six. Quality of life scores weighted by the participants' perception of importance and unweighted scores will be examined. A general linear model that includes the randomised group as a fixed factor will be used (unadjusted results), and models adjusting for baseline values will also be presented. The residual plots from these analyses will be visually inspected, and if reasonable normality is not apparent, alternative generalised linear models will be undertaken.

For the secondary outcomes, changes in scores from baseline to the end of the intervention will be analysed using appropriate statistical tests, depending on the data distribution. Descriptive statistics will be presented as frequencies, percentages, and mean $\pm$ (SD) for normally distributed parameters or medians (interquartile ranges) for non-normally distributed parameters with a 95% confidence interval and $p \leq 0.05$ value to show statistical significance. Appropriate statistical techniques shall be used to mitigate any potential confounders and shall be reported in subsequent publications of this study. No formal hypothesis testing will be conducted on these variables.

Stool microbiome data will be analysed using principal coordinate analysis and permutational multivariate ANOVA. Alpha-diversity and beta-diversity indices will be calculated. Differential abundance analysis of the microbiome abundance data (Analysis of Composition of Microbiomes with Bias Correction) [59] will be used to explore relationships between diet, metadata, diversity indices and microbiome taxonomic traits. All analyses will be done in R with probability values adjusted for multiple comparisons using the Benjamini-Hochberg method [60] and data reported according to the reporting guidelines for human microbiome research (STORMS) [61].

Ethical approval

The study was conducted in accordance with the International Conference of Harmonisation

guidelines, national and local requirements, and the ethical principles originating in the Declaration of Helsinki. Ethical approval was granted by the Northern B Health and Disability Ethics Committee (Reference: 20222 FULL 12734). Prior to commencement, the study was registered on the Australian New Zealand Clinical Trials Registry (ACTRN12622001140741p). All participants were required to date and sign an informed consent prior to participating in the study.

Results

Enrolment into the study began in December 2022 and was completed in September 2023. The intervention phase and data collection for the main study were completed in December 2023. A total of 75 participants were enrolled into the study. Seven participants withdrew before receiving the allocated intervention and were not included in the analysis, resulting in a final population of 68 participants (n=52, 76% female; n=16, 24% male). As of March 2024, data analysis of the PROs and laboratory analyses is being undertaken. The study's results will be disseminated in scientific manuscripts published in peer-reviewed journals and through abstracts, posters, and presentations at national and international conferences.

Discussion

FD is a common chronic gastrointestinal condition that can significantly affect the quality of life [16]. However, despite high prevalence rates, the pathophysiology is poorly understood [1, 4], limiting the development of effective treatment options [21]. These factors may lead people to seek alternative therapies, although the evidence supporting the effectiveness of such therapies is limited and inconclusive [19]. Honey has been used to treat digestive diseases, based primarily on anecdotal or pre-clinical research [22, 30, 38]. Emerging evidence suggests honey might promote healthy gut microbiota composition [27, 28, 62]. Mānuka honey has many unique bioactive compounds that might lend it to be an alternative treatment for FD. Although pre-clinical studies have shown

potential gastroprotective properties of mānuka honey, and recent *in vitro* evidence suggests the naturally occurring mānuka compound Lepteridine™ may modulate digestive inflammatory pathways, clinical studies are needed to explore and validate these findings. Recently, a pilot study reported a potential benefit of mānuka honey on symptoms of gastroesophageal reflux disease[63]. However, well designed clinical studies are yet to test these postulated benefits.

The SOOTHE study is a randomised, controlled, feasibility study designed to gather crucial information to inform the design and implementation of clinical trials to test the effects of Lepteridine™ standardised mānuka honey on FD symptoms and quality of life. The study involves a well-defined population group, identified using a validated diagnostic tool (ROME IV) and provides information on symptom severity using the validated SF-LDQ. In addition, using an intervention with a standardised formulation allows for consistent dosing.

Given the lack of prior clinical studies to inform this study design we were unable to power this study to detect a significant treatment effect; however, this study will provide information as to whether further investigation into mānuka honey for FD treatment is warranted. If a treatment effect is indicated, the information gathered will allow future studies to be well-designed and adequately powered. Frequent assessments during the study period will allow investigation into the time course of any potential treatment effects, allowing refining future study duration and study measurements.

The inclusion of two differing formulations of Lepteridine™ will provide an initial indication of a potential causal effect of Lepteridine™ in gastrointestinal health. The inclusion of biological assessments along with patient reported outcomes will contribute to the emerging knowledge about this poorly understood condition and can be used to support the interpretation of patient-reported results.

Declarations

Consent for publication

Data derived from this study will be the exclusive property of the Principal Investigators. No use or transmission to a third party will be made possible without their consent. The Principal Investigators will approve any publication or presentation related to the study. In addition, biological samples and participant data collected during this study may not be used by site investigators for research unrelated to this protocol without the prior approval of the Principal Investigators. Other legal aspects, including Intellectual Property, are covered by contracts between the High-Value Nutrition National Science Challenge – Ko Ngā Kai Whai Painga, University of Otago, Comvita New Zealand Ltd., Massey University and Malaghan Institute of Medical Research.

Protocol amendment

Any protocol changes that may affect the conduct of the study and the safety of participants, including changes in study objectives, study design, study population, and sample size, required a formal amendment to the protocol. There were amendments to the cut-off criteria for body mass index (BMI) from 18.5-35 kg/m² to 18.5-40 kg/m², allowing a wider scope of persons to be recruited into the study. Additionally, adjustments were made to the design of the Leptiridine™ acute study. Initially, the acute study was to be done during the baseline visit in a sub-group of five participants in each honey group. However, the design was adjusted to a crossover design with a one-week washout period as there is no information on the absorption and metabolism of Leptiridine™ honey in healthy persons. However, these changes were not considered significant, although the ethics committee was informed of the changes.

Funding

The study was funded by the High-Value Nutrition National Science Challenge, funded by the New Zealand Ministry of Business, Innovation and Employment, contract number (UOAX1902) and

Comvita NZ Ltd. Comvita NZ Ltd provided the study treatments: 10 mg/kg and 40 mg/kg Leperidine™ standardised mānuka honey and honey maple flavoured syrup.

Conflict of interest

T.L.M. and J.C.E. are employees of Comvita NZ Ltd, the industry partner. They had input on the study design and will have input on interpreting the results. The University of Otago researchers were involved in data collection, they will lead data analysis and will be responsible for final interpretation and decision to publish the results. The remaining authors declare that the research was conducted without any financial or commercial relationship that could be a conflict of interest.

Availability of data and materials

Not applicable. This is a study protocol which does not contain any data.

Acknowledgements

Acknowledgements go to the Scientific Advisory Board for their support in developing the study design, Dr Karin Schofield for managing the project's contract management, the study participants, and University of Otago support staff for helping with study logistics (Research and Enterprise Division of Health Sciences, Department of Human Nutrition Administrators, mailroom personnel, Stewart St Medical clinic receptionists) and assisting with study clinics (Marjory Still, Denise McWhinnie, Bryn Forrest and Dr Maryam Abshirini).

References

1. Mahadeva, S. and K.L. Goh, Epidemiology of functional dyspepsia: a global perspective. *World J Gastroenterol*, 2006. 12(17): p. 2661-6.
2. Sperber, A.D., et al., Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. *Gastroenterology*, 2021. 160(1): p. 99-114 e3.
3. Agata Mulak, T.F., Marek Waluga, Shrikant I. Bangdiwala, Olafur S. Palsson, Ami D. Sperber, Sex- and gender-related differences in the prevalence and burden of disorders of gut-brain interaction in Poland. *Neurogastroenterology and Motility*, 2023. 35(6): p e14568.
4. Holtmann, G., A. Shah, and M. Morrison, Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. *Dig Dis*, 2017. 35 Suppl 1: p. 5-13.
5. Park, S.Y., et al., Gastric Motor Dysfunction in Patients with Functional Gastroduodenal Symptoms. *Am J Gastroenterol*, 2017. 112(11): p. 1689-1699.
6. Carbone, F., et al., Relationship Between Gastric Emptying Rate and Simultaneously Assessed Symptoms in Functional Dyspepsia. *Clin Gastroenterol Hepatol*, 2022. 20(3): p. e429-e437.
7. Farre, R., et al., In Functional Dyspepsia, Hypersensitivity to Postprandial Distention Correlates with Meal-Related Symptom Severity. *Gastroenterology*, 2013. 145(3): p. 566-573.
8. Vanheel, H., et al., Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. *Am J Gastroenterol*, 2017. 112(1): p. 132-140.
9. Igarashi, M., et al., Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia. *BMJ Open Gastroenterology*, 2017. 4(1): p. e000144.
10. Zhong, L., et al., Dyspepsia and the microbiome: time to focus on the small intestine. *Gut*, 2017. 66(6): p. 1168-1169.
11. Hirohiko Nakae, A.T., Takashi Matsuoka, Tetsuya Mine, and Yasuhiro Koga, Gastric Microbiota in the Functional Dyspepsia Patients Treated with Probiotic Yogurt. *BMJ Open Gastroenterol*, 2016. 3(1): p. e000109.
12. Du, L.J., et al., Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study. *Scientific Reports*, 2016. 6: p. 34305
13. Vanheel, H., et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. *Gut*, 2014. 63(2): p. 262-71.
14. Jung, H.K., & Talley, N. J., Role of the Duodenum in the Pathogenesis of Functional Dyspepsia: A Paradigm Shift. *Journal of Neurogastroenterology and Motility*, 2018. 24(3): p. 345-354.
15. Aro, P., et al., Anxiety Is Linked to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up Study. *Gastroenterology*, 2015. 148(5): p. 928-37.
16. Frank, L., et al., Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. *Clin Ther*, 2002. 24(4): p. 675-89; discussion 674.
17. Brook, R.A., et al., Functional Dyspepsia Impacts Absenteeism and Direct and Indirect Costs. *Clinical Gastroenterology and Hepatology*, 2010. 8(6): p. 498-503.
18. Chuah, K.H., et al., Functional dyspepsia leads to more healthcare utilization in secondary care compared with other functional gastrointestinal disorders. *Journal of Digestive Diseases*, 2022. 23(2): p. 111-117.
19. Masuy, I., L. Van Oudenhove, and J. Tack, Review article: treatment options for functional dyspepsia. *Alimentary Pharmacology & Therapeutics*, 2019. 49(9): p. 1134-1172.

20. Matsushita, M., T. Masaoka, and H. Suzuki, Emerging treatments in neurogastroenterology: Acotiamide, a novel treatment option for functional dyspepsia. *Neurogastroenterology and Motility*, 2016. 28(5): p. 631-638.
21. Vakil, N., Treatment options for functional dyspepsia. *Digestive Diseases*, 2001. 19(3): p. 240-243.
22. Eteraf-Oskouei, T. and M. Najafi, Traditional and Modern Uses of Natural Honey in Human Diseases: A Review. *Iranian Journal of Basic Medical Sciences*, 2013. 16(6): p. 731-742.
23. Ball, D.W., The chemical composition of honey. *Journal of Chemical Education*, 2007. 84(10): p. 1643-1646.
24. Samarghandian, S., T. Farkhondeh, and F. Samini, Honey and Health: A Review of Recent Clinical Research. *Pharmacognosy Res*, 2017. 9(2): p. 121-127.
25. Mesaik, M.A., et al., Characterization of immunomodulatory activities of honey glycoproteins and glycopeptides. *J Agric Food Chem*, 2015. 63(1): p. 177-84.
26. Nooh, H.Z. and N.M. Nour-Eldien: The dual anti-inflammatory and antioxidant activities of natural honey promote cell proliferation and neural regeneration in a rat model of colitis. *Acta Histochem*, 2016. 118(6): p. 588-595.
27. Masad, R.J., et al., Oral administration of Manuka honey induces IFN γ -dependent resistance to tumor growth that correlates with beneficial modulation of gut microbiota composition. *Front Immunol*, 2024. 15: p. 1354297.
28. Shamala, T.R., Y. Shri Jyothi, and P. Saibaba, Stimulatory effect of honey on multiplication of lactic acid bacteria under in vitro and in vivo conditions. *Lett Appl Microbiol*, 2000. 30(6): p. 453-5.
29. Rita Narayanan, B.S.S., Effect of prebiotics on bifidobacterial species isolated from infant faeces. *Indian Journal of Traditional Knowledge*, 2015. 14(2): p. 285-289.
30. Mohtashami, R., et al., Efficacy and safety of honey-based formulation of *Nigella sativa* seed oil in functional dyspepsia: A double blind randomized controlled clinical trial. *J Ethnopharmacol*, 2015. 175: p. 147-52.
31. Taghvaei, T., M. Bagheri-Nesami, and A. Nikkhah, The Effect of Honey and Diet Education on Symptoms of Functional Dyspepsia: A Randomized Clinical Trial. *Iranian Red Crescent Medical Journal*, 2018. 20(8): p. e65557.
32. Mamdouh Abdulkhamsoud Abdulrhman, Y. and A.A.E.S. Mohamed Mohsen Awad, Bee Honey as an Adjuvant Therapeutic Modality for Children with Functional Dyspepsia. *QJM: An International Journal of Medicine*, 2024. 117.
33. Alvarez-Suarez, J.M., et al., The Composition and Biological Activity of Honey: A Focus on Manuka Honey. *Foods*, 2014. 3(3): p. 420-432.
34. El-Senduny, F.F., et al., Manuka honey, a unique mono-floral honey. A comprehensive review of its bioactives, metabolism, action mechanisms, and therapeutic merits. *Food Bioscience*, 2021. 42: p. 101038.
35. Almasaudi, S.B., et al., Manuka Honey Exerts Antioxidant and Anti-Inflammatory Activities That Promote Healing of Acetic Acid-Induced Gastric Ulcer in Rats. *Evidence-Based Complementary and Alternative Medicine*, 2017. 2017: p. 5413917.
36. Prakash, A., et al., Effect of Different Doses of Manuka Honey in Experimentally Induced Inflammatory Bowel Disease in Rats. *Phytotherapy Research*, 2008. 22(11): p. 1511-1519.
37. Almasaudi, S.B., et al., Antioxidant, Anti-inflammatory, and Antiulcer Potential of Manuka Honey against Gastric Ulcer in Rats. *Oxidative Medicine and Cellular Longevity*, 2016. 2016: p. 3643824.
38. Medhi, B., et al., Effect of Manuka honey and sulfasalazine in combination to promote

- antioxidant defense system in experimentally induced ulcerative colitis model in rats. *Indian Journal of Experimental Biology*, 2008. 46(8): p. 583-590.
39. Du, Y., et al., Study on the antiulcer effects of *Veronicastrum axillare* on gastric ulcer in rats induced by ethanol based on tumor necrosis factor-alpha (TNF-alpha) and endothelin-1 (ET-1). *Asian Pac J Trop Biomed*, 2013. 3(12): p. 925-30.
 40. Lin, B., et al., Lepteridine as a unique fluorescent marker for the authentication of manuka honey. *Food Chemistry*, 2017. 225: p. 175-180.
 41. Carmona-Martinez, V., et al., Therapeutic potential of pteridine derivatives: A comprehensive review. *Med Res Rev*, 2019. 39(2): p. 461-516.
 42. Lin, B., et al., The *Leptospermum scoparium* (Manuka)-Specific Nectar and Honey Compound 3,6,7-Trimethylumazine (Lepteridine(TM)) That Inhibits Matrix Metalloproteinase 9 (MMP-9) Activity. *Foods*, 2023. 12(22): p. 4072.
 43. Matusiewicz, M., et al., Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. *Dis Markers*, 2014. 2014: p. 643645.
 44. Moore, B.A., et al., Matrix metalloproteinase-9 inhibition reduces inflammation and improves motility in murine models of postoperative ileus. *Gastroenterology*, 2011. 141(4): p. 1283-92, 1292 e1-4.
 45. Chan, A.W., et al., SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*, 2013. 158(3): p. 200-7.
 46. Foundation, R., The Short-Form Leeds Dyspepsia Questionnaire validation study. 2006.
 47. A. Fraser, B.C.D., A. C. Ford , M. Qume & P. Moayyedi, The Short-Form Leeds Dyspepsia Questionnaire validation study. *Alimentary Pharmacology & Therapeutics*, 2007. 25(4): p. 477-486.
 48. Jones, M.P., Y.A. Sato, and N.J. Talley, The Nepean Dyspepsia Index is a valid instrument for measuring quality-of-life in functional dyspepsia. *Eur J Gastroenterol Hepatol*, 2019. 31(3): p. 329-333.
 49. Jones, M. and N.J. Talley, Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia. *Am J Gastroenterol*, 2009. 104(6): p. 1483-8.
 50. Talley, N.J., et al., Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. *Aliment Pharmacol Ther*, 1999. 13(2): p. 225-35.
 51. Cella, D., et al., The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. *J Clin Epidemiol*, 2010. 63(11): p. 1179-94.
 52. Spiegel, B.M., et al., Understanding gastrointestinal distress: a framework for clinical practice. *Am J Gastroenterol*, 2011. 106(3): p. 380-5.
 53. Shokouhi, N., et al., Development of a new version of the Bristol Stool Form Scale: translation, content validity, face validity, and reliability of the Persian version. *BMJ Open Gastroenterol*, 2022. 9(1).
 54. Zhang, T., et al., The newest Oxford Nanopore R10.4.1 full-length 16S rRNA sequencing enables the accurate resolution of species-level microbial community profiling. *Applied and Environmental Microbiology*, 2023. 89(10): p. e00605-23.
 55. Ishisaka, A., et al., In vivo absorption and metabolism of leptosperin and methyl syringate, abundantly present in manuka honey. *Mol Nutr Food Res*, 2017. 61(9).
 56. Wishart, D.S., et al., BioTransformer 3.0-a web server for accurately predicting metabolic transformation products. *Nucleic Acids Res*, 2022. 50(W1): p. W115-W123.
 57. Harris, P.A., et al., Research electronic data capture (REDCap)--a metadata-driven

- methodology and workflow process for providing translational research informatics support. *J Biomed Inform*, 2009. 42(2): p. 377-81.
58. Harris, P.A., et al., The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*, 2019. 95: p. 103208.
 59. Lin, H. and S.D. Peddada, Analysis of compositions of microbiomes with bias correction. *Nat Commun*, 2020. 11(1): p. 3514.
 60. Benjamin Yoav, Y.H., Controlling the False Discovery Rate: A practical and Powerful Approach to Multiple Testing. *Journal of Royal Statistical Society*, 1995. 57(1): p. 289-300.
 61. Mirzayi, C., et al., Reporting guidelines for human microbiome research: the STORMS checklist. *Nat Med*, 2021. 27(11): p. 1885-1892.
 62. Ezz El-Arab, A.M., et al., Effect of dietary honey on intestinal microflora and toxicity of mycotoxins in mice. *BMC Complement Altern Med*, 2006. 6: p. 6.
 63. Goslinski, M., et al., Application of Manuka honey in treatment patients with GERD. *Food Sci Nutr*, 2024. 12(1): p. 172-179.

Abbreviations

BMI: Body mass index

FD: Functional Dyspepsia

IL: Interleukin

MMP-9: Matrix Metalloproteinase-9

NDI: Nepean Dyspepsia Index

PBMC: Peripheral Blood Mononuclear cells

PROMIS: Patient-Reported Outcome Measurement Information System

REDCap: Research Electronic Data Capture

SF-LDQ: Short Form Leeds Dyspepsia Questionnaire

SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials

STORMS: Strengthening The Organizing and Reporting of Microbiome Studies

TNF- α : tumour necrosis factor-alpha

Appendix 1

Isolation of peripheral blood mononuclear cells (PBMC)

1. The blood collected in the 3 x 10 mL vacutainers was poured evenly into 2-3 sterile 50 mL centrifuge tubes.
2. Blood volume was matched (up to 30 mL maximum) with PBS.
3. Lymphoprep™ (15 mL) was added into the bottom section of each of the SepMate™-50 tubes.
4. The diluted blood from each of the tubes was gently pipetted down the side of each of the prepared SepMate™-50 tubes and centrifuged at 1,200 x g (RT, 10 minutes, Acceleration: 9, Deceleration: 9) on a swing-bucket centrifuge to separate the various blood components.
5. The top layer was then poured into sterile 50 mL centrifuge tubes, avoiding red blood cell contamination, topped up to 50 mL with PBS and centrifuged at 300 x g (RT, 8 minutes, Acceleration: 9, Deceleration: 9).
6. The supernatant was discarded to remove the plasma and residual Lymphoprep™.
7. Pelleted cells were pooled and resuspended in 10 mL PBS, and 10 µl was taken for cell counting.
8. The tube was centrifuged at 300 x g, and the supernatant was discarded.
9. The PBMC pellet was resuspended in the freezing mixture (90% HI-FBS:10% (v/v) DMSO) at a concentration of ca. 1×10^7 cells/mL and aliquoted into pre-labelled cryovials.
10. The cryovials were transferred into a CoolCell® LX freezer container and kept at -80°C overnight to slowly freeze the cells before transfer into a liquid nitrogen dewar.

Supplementary Files

Figures

Study Flow Chart.




Figure 1. Study flow chart; BID (bis in die): 10 g of allocated intervention twice daily, before breakfast and dinner.

CONSORT (or other) checklists

SPIRIT CHECKLIST.

URL: <http://asset.jmir.pub/assets/da0e720fd0e053759c2a38aa2a53670a.pdf>

Revised SPIRIT Checklist.

URL: <http://asset.jmir.pub/assets/9020cdced6ac715edb20c623d9bc0796.pdf>

